EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Liver cyst penetration of antibiotics at the target site of infection: a randomized pharmacokinetic trial

Lucas H P Bernts iD, Roger J M Brüggemann iD, Anouk M E Jansen iD, Nynke G L Jager iD, Heiman F L Wertheim, Joost P H Drenth, Marten A Lantinga

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkae394 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Lucas H P Bernts und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherland…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Cysts, Doxycycline, Trimethoprim, Sulfamethoxazole Drug Combination. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Radboud University Medical Center, Stichting Dr. C.J. Vaillantfonds.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The EASL cystic liver disease guideline states that drug penetration at the site of infection (liver cyst) is essential for successful treatment, but pharmacokinetic (PK) data on cyst penetration are limited.

Objectives

This study aims to investigate tissue penetration of four antibiotics in non-infected liver cysts and explores influencing factors.

Methods

We performed a prospective, randomized single-dose PK-study. Before percutaneous drainage of a non-infected liver cyst, an intravenous (IV) dose of either ciprofloxacin and piperacillin/tazobactam (group 1); or co-trimoxazole (trimethoprim/sulfamethoxazole) and doxycycline (group 2) was given. Cyst fluid was collected during drainage. Blood samples were obtained before, during and after drainage (within 12 h). Drug concentrations were measured with a validated LC-MS/MS. Primary outcome was liver cyst penetration, defined as the cyst-fluid-to-plasma concentration ratio (%) expressed as median (IQR).

Results

We included 20 patients, and 21 liver cysts were drained (group 1: n = 11, group 2: n = 10). Median drained cyst volume was 700 mL. Median time between infusion and drainage was 139 min (IQR 120–188 min). Median cyst-fluid-to-plasma concentration ratio was 4.2% (IQR 1.6%–8.9%) for ciprofloxacin, 0.3% (IQR 0.0%–1.3%) for piperacillin, 0.2% (IQR 0.0%–1.3%) for tazobactam, 12.2% (IQR 6.3%–16.1%) for trimethoprim, 0.4% (IQR 0.2%–3.8%) for sulfamethoxazole and 1.6% (IQR 0.9%–2.3%) for doxycycline. Time between trimethoprim infusion and cyst drainage was correlated with increased cyst-fluid-to-plasma concentration ratio (P < 0.01).

Conclusions

Trimethoprim and ciprofloxacin have the highest penetration ratios amongst antibiotics tested. We found that liver cyst penetration varies widely between drugs after a single IV dose. Clinical trial number NTR8499 The trial was originally registered in the Netherlands Trial Register (ID: NL7290), which was converted to the International Clinical Trials Registry Platform in 2022.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsCystsDoxycyclineTrimethoprim, Sulfamethoxazole Drug CombinationHumansMaleFemaleMiddle AgedProspective StudiesAgedCiprofloxacinLiver DiseasesAdultPiperacillin, Tazobactam Drug CombinationDrainage

Substanzen

Anti-Bacterial AgentsDoxycyclineTrimethoprim, Sulfamethoxazole Drug CombinationCiprofloxacinPiperacillin, Tazobactam Drug Combination

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Medical Microbiology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hamburg, Germany.
  • Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, The Netherlands.

ORCID-Profile: Lucas H P Bernts, Roger J M Brüggemann, Anouk M E Jansen, Nynke G L Jager

Förderung

  • Radboud University Medical Center
  • Stichting Dr. C.J. Vaillantfonds

Zitieren

APA

Bernts, L. H. P., Brüggemann, R. J. M., Jansen, A. M. E., Jager, N. G. L., Wertheim, H. F. L., Drenth, J. P. H., & Lantinga, M. A. (2025). Liver cyst penetration of antibiotics at the target site of infection: a randomized pharmacokinetic trial. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae394

Vancouver

Bernts LHP, Brüggemann RJM, Jansen AME, Jager NGL, Wertheim HFL, Drenth JPH, et al. Liver cyst penetration of antibiotics at the target site of infection: a randomized pharmacokinetic trial. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkae394

BibTeX
@article{Bernts2025,
  author = {Bernts, Lucas H P and Brüggemann, Roger J M and Jansen, Anouk M E and Jager, Nynke G L and Wertheim, Heiman F L and Drenth, Joost P H and Lantinga, Marten A},
  title = {Liver cyst penetration of antibiotics at the target site of infection: a randomized pharmacokinetic trial},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkae394}
}
Kostenlos starten →